Sino Biopharmaceutical (OTCMKTS:SBMFF) Upgraded by Zacks Investment Research to “Hold”

Zacks Investment Research upgraded shares of Sino Biopharmaceutical (OTCMKTS:SBMFF) from a sell rating to a hold rating in a research note issued to investors on Wednesday, reports.

According to Zacks, “Sino Biopharmaceutical Limited researches, develops, produces and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis. Sino Biopharmaceutical Limited is headquartered in Wanchai, Hong Kong. “

Separately, ValuEngine upgraded Sino Biopharmaceutical from a strong sell rating to a sell rating in a research report on Monday.

Shares of OTCMKTS SBMFF traded down $0.01 during midday trading on Wednesday, hitting $1.52. 800 shares of the company’s stock were exchanged, compared to its average volume of 2,575. The stock’s 50 day moving average price is $1.38 and its 200-day moving average price is $1.17. Sino Biopharmaceutical has a twelve month low of $0.58 and a twelve month high of $1.53.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, researches, develops, manufactures, and sells Chinese medicines and chemical medicines in Hong Kong, Mainland China, and internationally. The company operates in Modernized Chinese Medicines and Chemical Medicines, Investment, and Others segments. Its principal products include hepatitis medicines, such as Runzhong dispersible tablets, Tianqingganmei injections, Tianqingganping enteric capsules, Tianding tablets, Mingzheng capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Kaishi injections, Yilunping and Tuotuo tablets, Tianqingning injections, and Beraprost Sodium tablets; and oncology medicines consisting of Zhiruo, Saiweijian, Tianqingyitai, and Qingweike injections, as well as Shoufu and Yinishu tablets, and Gelike capsules.

See Also: What is the significance of the death cross?

Get a free copy of the Zacks research report on Sino Biopharmaceutical (SBMFF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Sino Biopharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sino Biopharmaceutical and related companies with's FREE daily email newsletter.